Market Place
Sourcing Support
FDA Accepts NDA in Metastatic Hormone-Sensitive Prostate Cancer
21 Nov 2024 //
BUSINESSWIRE
Bayer applies for third indication of Nubeqa in EU
14 Oct 2024 //
REUTERS
Bayer Submits sNDA For NUBEQA In Prostate Cancer
26 Sep 2024 //
BUSINESSWIRE
Nubeqa Reduces Progression Risk In Prostate Cancer Trial
16 Sep 2024 //
BUSINESSWIRE
Darolutamide Plus ADT Reduces Prostate Cancer Progression
16 Sep 2024 //
GLOBENEWSWIRE
Bayer hopes to expand Nubeqa`s prostate cancer reach with chemo-free regimen
16 Sep 2024 //
FIERCE PHARMA
Bayer To Present New Prostate Cancer Data At ESMO 2024
05 Sep 2024 //
BUSINESSWIRE
ORIC Pharmaceuticals Reports Q2 2024 Results And Operational Updates
12 Aug 2024 //
GLOBENEWSWIRE
Darolutamide Phase III ARANOTE Trial Meets Primary Endpoint
17 Jul 2024 //
PRESS RELEASE
Bayer eyes wider Nubeqa use on new prostate cancer trial data
17 Jul 2024 //
REUTERS
Darolutamide: A Promising Advancement in Prostate Cancer Treatment
07 Jun 2024 //
PRESS RELEASE
Bayer reports drop in Q1 sales amidst patent litigation challenges
14 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Bayer Pharmaceuticals advances next generation of blockbuster medicines
21 Mar 2024 //
PRESS RELEASE
FDA Confirms Paragraph IV Patent Litigation for Darolutamide Tablets
08 Sep 2023 //
FDA
Celcuity Enters into Collaboration with Bayer to Provide Nubeqa
22 Aug 2023 //
GLOBENEWSWIRE
Bayer`s Nubeqa, AZ`s Forxiga pick up nods from UK`s NICE
22 May 2023 //
FIERCE PHARMA
Bayer`s potential blockbusters Nubeqa, Kerendia thrive in Q1
11 May 2023 //
FIERCE PHARMA
Bayer Expands Global Clinical Program for NUBEQA in Prostate Cancer
23 Mar 2023 //
BUSINESSWIRE
Orion & Bayer expand clinical development program for darolutamide
23 Mar 2023 //
GLOBENEWSWIRE
Darolutamide approved for additional prostate cancer indication in China
21 Mar 2023 //
GLOBENEWSWIRE
Darolutamide receives approval for additional prostate cancer indication
27 Feb 2023 //
GLOBENEWSWIRE
New NUBEQA Subgroup Analyses from PIII ARASENS Trial in mHSPC Patients
16 Feb 2023 //
BUSINESSWIRE
Positive CHMP opinion for darolutamide in combination with docetaxel for mHSPC
27 Jan 2023 //
GLOBENEWSWIRE
NHS expedites rollout of Bayer’s darolutamide for prostate cancer
29 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
Bayer`s Nubeqa debuts in new use across the pond
28 Nov 2022 //
FIERCEPHARMA
MHRA, NHS England make available new prostate cancer treatment
28 Nov 2022 //
PHARMAPHORUM
Health Canada approves additional indication for NUBEQA® (darolutamide)
05 Oct 2022 //
BAYER
New ARASENS data reinforce strong tolerability profile of darolutamide
11 Sep 2022 //
PRESS RELEASE
Bayer`s Nubeqa nabbed a second prostate cancer indication
09 Aug 2022 //
FIERCEPHARMA
U.S. FDA approves additional indication of darolutamide + docetaxel
08 Aug 2022 //
GLOBENEWSWIRE
U.S. FDA Approves Additional Indication of NUBEQA in Combination with Docetaxel
05 Aug 2022 //
BUSINESSWIRE
Darolutamide plus androgen deprivation therapy & docetaxel demonstrate OS benefits
04 Jul 2022 //
PRESS RELEASE
FDA accepts sNDA and grants priority review for addn indication of darolutamide
03 May 2022 //
GLOBENEWSWIRE
Bayer Submits Applications for Additional Indication of NUBEQA (darolutamide)
09 Mar 2022 //
BUSINESSWIRE
Trial results deliver hope for prostate cancer patients
18 Feb 2022 //
PHARMATIMES
Bayer tees up new 3-way battle against Pfizer-Astellas, J&J
18 Feb 2022 //
FIERCEPHARMA
Results from Phase III Show NUBEQA + ADT and Docetaxel Increases OS in mHSPC
17 Feb 2022 //
BUSINESSWIRE
Bayer and Orion’s Nubeqa phase III ARASENS trial meets primary endpoint
06 Dec 2021 //
PHARMABIZ
Bayer`s Nubeqa triumphs in metastatic prostate cancer
04 Dec 2021 //
FIERCEPHARMA
ARASENS trial with darolutamide in combination with docetaxel and androgen
02 Dec 2021 //
GLOBENEWSWIRE
NUBEQA Impact on Local Symptoms Evaluated in Men with nmCRPC
14 Sep 2021 //
BUSINESSWIRE
FDA finalizes guidance on metastasis-free survival as an endpoint
06 Aug 2021 //
RAPS
ESSA Pharma Announces Clinical Collaboration Agreement with Bayer
28 Apr 2021 //
PRNEWSWIRE
Bayer`s `AMI` voice assistant talks about drug info with docs
19 Apr 2021 //
FIERCEPHARMA
Bayer receives approval for Nubeqa™ in China for the treatment of men
03 Feb 2021 //
PRESS
U.S. FDA Approves Addition of Overall Survival and Endpoint Data to NUBEQA®
08 Jan 2021 //
BUSINESSWIRE
Scottish Medicines Consortium greenlights Nubeqa for prostate cancer
10 Nov 2020 //
PHARMAFILE
Bayer`s Nubeqa secures NICE recommendation for hormone-relapsed prostate cancer
23 Oct 2020 //
PHARMAFILE
Ad Hoc Analysis of ARAMIS Showed a High Percentage (97.2%)
21 Sep 2020 //
BUSINESSWIRE
New England Journal of Medicine Publishes Final Data for NUBEQA (darolutamide)
09 Sep 2020 //
BUSINESSNEWSWIRE
Darolutamide in prostate cancer: indication of considerable added benefit
03 Aug 2020 //
IQWING
Kangpu to Present Two Posters at the 2020 (AACR) Annual Meeting
17 Jun 2020 //
PRNASIA
Sales of darolutamide started in the EU and Japan Orion receives of EUR 28M
20 May 2020 //
GLOBENEWSWIRE
NUBEQA® (darolutamide) Plus Androgen Deprivation Therapy Showed a Statistically
13 May 2020 //
BUSINESSWIRE
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20
11 May 2020 //
BUSINESSWIRE
Bayer AG Nubeqa (darolutamide) Receives Approval in Europe
04 Apr 2020 //
EMA
Bayer gets EU nod for prostate cancer drug Nubeqa
01 Apr 2020 //
PMLIVE
Nubeqa authorised in Europe for certain prostate cancer patients
31 Mar 2020 //
PHARMA TIMES
